Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Estrone Sulfuric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 2/20 | 0.73 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | STS | P08842 | 9/20 | 0.90 |
| ▸ | ABCC4 | O15439 | 3/20 | 0.90 |
| ▸ | ABCC1 | P33527 | 2/20 | 0.90 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.90 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.90 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.73 |
| ▸ | CA1 | P00915 | 2/20 | 0.73 |
| ▸ | CA2 | P00918 | 2/20 | 0.73 |
| ▸ | CA9 | Q16790 | 2/20 | 0.73 |
| ▸ | CA4 | P22748 | 1/20 | 0.73 |
| ▸ | CA6 | P23280 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | MAPT | P10636 | 2/20 | 0.69 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.69 |
| ▸ | RECQL | P46063 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Estrone Sulfuric Acid SCHEMBL4443808 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL21577 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL6556684 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL29366794 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL7216979 | 1.00 | CYP3A4 (1.00) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL19100296 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL6931138 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL14844580 | 0.99 | CYP3A4 (0.98) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL23834600 | 0.96 | CYP3A4 (0.93) | CYP3A4STSABCC4ABCC1CYP2C9 | |
| Estrone Sulfuric Acid SCHEMBL10772904 | 0.96 | CYP3A4 (0.93) | CYP3A4STSABCC4ABCC1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1005 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3651746-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | Hera Health Solutions Inc. (US) | 2020-05-20 | — | — | EP | claimed |
| WO-2019014076-A1 | BIOERODIBLE DRUG DELIVERY IMPLANTS | HERA HEALTH SOLUTIONS INC. (US) | 2019-01-17 | — | — | WO | claimed |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | BAUSCH HEALTH IRELAND LIMITED (F/K/A/ VALEANT PHARMACEUTICALS IRELAND LIMITED) (IE) | 2015-11-12 | — | — | US | claimed |
| CN-104825397-A | Controlled release delivery device containing organosol coating | ISA ODIDI | 2015-08-12 | — | — | CN | claimed |
| CN-101370453-B | Compositions and methods for dermal delivery of drugs | NUVO RES INC | 2013-12-18 | — | — | CN | claimed |
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. (US) | 2013-08-08 | — | — | US | claimed |
| US-8288366-B2 | Formulation for hair growth | CHOCHINOV RONALD H (US) | 2012-10-16 | — | — | US | claimed |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | SPROUT PHARMACEUTICALS, INC. | 2011-05-05 | — | — | US | claimed |
| EP-0930876-B2 | USE OF COMPOUNDS THAT PROMOTE OESTROGENIC ACTIVITY FOR ACCLERATING THE HEALING OF SKIN WOUNDS | RENOVO LTD (GB) | 2010-07-07 | — | — | EP | claimed |
| US-20100120707-A1 | Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administering same | PLAYTEX PRODUCTS, LLC | 2010-05-13 | — | — | US | claimed |
| EP-0538443-A4 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | — | 1993-12-08 | — | — | EP | claimed |
| EP-0559240-A2 | Hormone composition containing estrogen and mogestin | JENCAP RESEARCH LIMITED (CA) | 1993-09-08 | — | — | EP | claimed |
| US-5211952-A | Drug delivery of gonadotropin hormone releasing hormones for time release | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1993-05-18 | — | — | US | claimed |
| EP-0538443-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS. | UNIV SOUTHERN CALIFORNIA (US) | 1993-04-28 | — | — | EP | claimed |
| WO-1992018107-A1 | METHODS AND FORMULATIONS FOR USE IN INHIBITING CONCEPTION AND IN TREATING BENIGN GYNECOLOGICAL DISORDERS | THE UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 1992-10-29 | — | — | WO | claimed |
| US-5108995-A | HORMONE PREPARATION AND METHOD | JENCAP RESEARCH LTD. (CA) | 1992-04-28 | — | — | US | claimed |
| US-4980358-A | Method employing gonadal hormones and dopamine agonist intended for combined use in the improvement of lymphocyte function | McAdory, George D. (US) | 1990-12-25 | — | — | US | claimed |
| CN-1041528-A | HORMONE PREPARATION AND METHOD | JENCAP RESEARCH LTD (CA) | 1990-04-25 | — | — | CN | claimed |
| US-4826831-A | Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens | PRE JAY HOLDINGS LIMITED (CA) | 1989-05-02 | — | — | US | claimed |
| EP-0309263-A2 | Hormone composition and use | JENCAP RESEARCH LIMITED (CA) | 1989-03-29 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203766-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885CYP3A4 867/4885STS 189/4885 |
| US-20110105519-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885CYP3A4 867/4885STS 189/4885 |
| US-20150320739-A1 | Pharmaceutical Compositions for the Treatment of Sexual Disorders II | FLNB, FLNA, FGB | ESR1 303/4885CYP3A4 867/4885STS 189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.